Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.59 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112600 | 0.99 | HRH3 (0.61) | HRH3IRAK1FGFR1FGFR2FGFR4 | |
| SCHEMBL481185 | 0.90 | HRH3 (0.66) | HRH3BUB1LMNAMAPK1NPY5R | |
| SCHEMBL2112767 | 0.89 | HRH3 (0.67) | HRH3BUB1LMNAMAPK1NPY5R | |
| SCHEMBL2113308 | 0.89 | HRH3 (0.62) | HRH3BUB1LMNAMAPK1 | |
| SCHEMBL2111126 | 0.89 | HRH3 (0.59) | HRH3BUB1NPY5R | |
| SCHEMBL2113296 | 0.88 | HRH3 (0.61) | HRH3BUB1LMNAMAPK1NPY5R | |
| SCHEMBL2111151 | 0.87 | HRH3 (0.62) | HRH3LMNAMAPK1NPY5R | |
| SCHEMBL2112076 | 0.86 | HRH3 (0.59) | HRH3NPY5R | |
| SCHEMBL13675015 | 0.86 | HRH3 (0.58) | HRH3LMNAMAPK1NPY5R | |
| SCHEMBL2112470 | 0.85 | HRH3 (0.60) | HRH3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | HRH3 2984/4885IRAK1 582/4885FGFR1 4164/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | HRH3 2984/4885IRAK1 582/4885FGFR1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.